https://www.selleckchem.com/products/u73122.html
Most breast cancers are hormone receptor-positive, and tamoxifen is the mainstay of endocrine therapy for such patients. However, with the introduction of aromatase inhibitors and then fulvestrant, tamoxifen became a less preferred drug, even in a premenopausal setting. Many new approaches to tackle the recently identified resistance pathways for endocrine therapy are widely used. Cyclin-dependent kinase 4/6 inhibitors such as ribociclib, palbociclib, and abemaciclib, and inhibitors of the mechanistic target of rapamycin such as everolim
Like
Comment
Share
